Navigation Links
Bionovo Reports First Quarter 2008 Financial Results
Date:5/9/2008

EMERYVILLE, Calif., May 9 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced results for the first quarter of 2008.

Quarter Results

The company did not report any revenue for the three months ended March 31, 2008. Revenues for the three months ended March 31, 2007 were $3,750, received from our licensing and technology transfer agreement with United Biotechnology Corporation of Taiwan. In October of 2007, we terminated the agreement following notice of material breach of the Agreement by UBC and we recognized the remaining deferred revenue of $91,250 in December 2007.

Total operating expenses for the three months ending March 31, 2008 were $4.2 million compared to $3.5 million for the same period in 2007.

The company reported a net loss for the three months ended March 31, 2008 of $3.9 million, or $0.05 per share, compared with a net loss of $3.3 million, or $0.05 per share, for the same period in 2007.

The Company ended the quarter with $29.4 million in cash, cash equivalents and short term investments, and began the quarter with $33.3 million, a difference of $3.9 million.

Company Highlights

-- Patient enrollment and dosing continues in the Phase 1 portion of the

BZL101 Phase 1/2 clinical trial for advanced metastatic breast cancer.

Presentations, papers and scientific discussions have expounded the

mechanisms of action and described the positive progress to date.

-- Bionovo presented data on two additional preclinical anti-cancer drug

candidates -- BN107 and BN108 -- at the American Association of Cancer

Research (AACR) conference in April. BN107 induces apoptosis through

the mitochondrial path
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
2. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
3. Louis Drapeau Joins Bionovos Board of Directors
4. George Butler Joins Bionovos Board of Directors
5. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
6. Bionovo Announces Third Quarter 2007 Financial Results
7. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
8. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
9. Bionovo Announces Proposed Public Offering of Common Stock
10. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
11. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Naurex Inc., a biopharmaceutical ... for diseases of the central nervous system, today announced ... executive officer, will present at the 33 rd ... take place at 3:00 p.m. PST on Tuesday, January ... San Francisco, Calif. ...
(Date:12/19/2014)... 18, 2014 BioPlus Specialty ... specialty pharmacies, has an expanded team of Regional ... consultants for prescriber offices in their regions, with ... “We have a variety of Regional Pharmaceutical Care ... specializing in hepatitis C help prescribers understand all ...
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 iLab ... announced the appointment of Siri Bryant as the new ... new Director of Core Implementations. These two new leadership ... outstanding customer service by ensuring that iLab continues to ... “In the last four years, iLab has been deployed ...
(Date:12/19/2014)... MILLBROOK, N.Y. , Dec. 18, 2014 Egenix, ... has been elected Chairman of the Board, to succeed ... President and CEO, but will continue as a member of ... that he has added to the company over almost twenty ... The Board of Directors has established a Search ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... Calif., July 7, 2011 InterMune (NASDAQ: ... in ASCEND, a new Phase 3 study of pirfenidone ...  ASCEND is a multinational, randomized, double-blind, placebo controlled Phase ... of Esbriet® (pirfenidone) in IPF patients with mild to ...
... America, Inc . ( www.cordblood-america.com ) (OTC Bulletin Board: ... preservation company focused on bringing the life saving potential ... today that CorCell, its domestic brand for cord blood stem ... Rewards Program in the U.S. for the collection of a ...
... a.m. EDT, the space shuttle Atlantis will streak skyward from ... mission. While the STS-135 flight marks the end of the ... new era of research into infectious diseases, thanks to space ... III, along with their colleagues at Arizona State University,s Biodesign ...
Cached Biology Technology:InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF 2InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF 3InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF 4InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF 5CorCell, a Cord Blood America Company, Launches Referral Rewards Program 2Final countdown: Atlantis to carry next-generation vaccine candidate on last space voyage 2Final countdown: Atlantis to carry next-generation vaccine candidate on last space voyage 3Final countdown: Atlantis to carry next-generation vaccine candidate on last space voyage 4
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Munich, Germany March 2, 2009 >> Genomatix Software, ... of Next Generation Sequencing (NGS) data, announced today that ... Genomatix Mining Station and a Genomatix Genome Analyzer at ... deliver the only complete and integrated analysis solution for ...
... An international team of scientists, led by Monash University ... kills elderly hospital patients worldwide - a discovery that ... systems billions of dollars each year. The research ... , unravelled ways to genetically modify the bacterium ...
... a picky preschooler who,s avoiding their vegetables? A new Cornell ... like X-Ray Vision Carrots and Tomato Bursts left preschoolers ... carrots called "X-ray Vision Carrots" ate nearly twice as much ... simply labeled as "carrots." The Robert Wood Johnson-funded study also ...
Cached Biology News:Boehringer Ingelheim uses Genomatix' Next Generation Sequencing data analysis systems 2Monash scientists debug superbug 2
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
... histochemically detect specific senescence ... in cultured cells and ... marker is only present ... found in presenescent/quiescent/immortal cells. ...
TAR DNA binding protein...
... BL21 Star strains are ... for improved protein yield ... systems (Figure 1). Because ... synthesizes mRNA more rapidly ...
Biology Products: